About absci corp - ABSI
Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
ABSI At a Glance
Absci Corp.
18105 SE Mill Plain Boulevard
Vancouver, Washington 98683
| Phone | 1-360-949-1041 | Revenue | 2.80M | |
| Industry | Biotechnology | Net Income | -115,183,000.00 | |
| Sector | Health Technology | Employees | 140 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ABSI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 170.483 |
| Price to Book Ratio | 2.791 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.995 |
| Enterprise Value to Sales | 120.843 |
| Total Debt to Enterprise Value | 0.016 |
ABSI Efficiency
| Revenue/Employee | 20,000.00 |
| Income Per Employee | -822,735.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.013 |
ABSI Liquidity
| Current Ratio | 6.57 |
| Quick Ratio | 6.57 |
| Cash Ratio | 6.338 |
ABSI Profitability
| Gross Margin | -319.357 |
| Operating Margin | -4,454.214 |
| Pretax Margin | -4,111.214 |
| Net Margin | -4,113.679 |
| Return on Assets | -53.585 |
| Return on Equity | -62.501 |
| Return on Total Capital | -59.144 |
| Return on Invested Capital | -61.123 |
ABSI Capital Structure
| Total Debt to Total Equity | 2.799 |
| Total Debt to Total Capital | 2.722 |
| Total Debt to Total Assets | 2.451 |
| Long-Term Debt to Equity | 1.385 |
| Long-Term Debt to Total Capital | 1.347 |